Medindia

X

DUSA Pharmaceuticals, Inc.(R) Announces Second Quarter Financial Results and Corporate Highlights Conference Call

Friday, September 18, 2009 General News J E 4
Advertisement


WILMINGTON, Mass., Aug. 6 DUSA Pharmaceuticals, Inc. (Nasdaq GM: DUSA) announces that its corporate highlights and second quarter financial results press release will be issued on Tuesday, August 11 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.

Tuesday, August 11 - 8:30 a.m. E.T.

If calling from the US or Canada use the following toll-free number:

800.647.4314

Password - DUSA

For International callers use

502.498.8422

A recorded replay of the call will be available approximately 15 minutes following the call

North American callers 877.863.0350

International callers 858.244.1268

The call will be accessible on our web site approximately four hours following the call at www.dusapharma.com.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(R) photodynamic therapy (PDT) technology platform, and complementary dermatology products. Levulan(R) PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(R). DUSA is researching Levulan(R) PDT for the treatment of AKs and the reduction of new non-melanoma skin cancer (NMSC) in chronically immunosuppressed solid organ transplant recipients (SOTRs). In addition, DUSA is supporting research related to oral leukoplakia in collaboration with National Institutes of Health (NIH). DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.

SOURCE DUSA Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
EANS-News: Alapis Announces its Share Capital Incr...
S
Stereotaxis Names Daniel Johnston as Chief Financi...